DelMar Pharma

DMPI NASDAQ
2.350
-0.090
-3.69%
盘后: 2.280 +0.03 +1.33% 16:00 05/17 EDT
开盘
2.510
昨收
2.440
最高
2.510
最低
2.250
成交量
3.31万
成交均量(3M)
4.87万
52周最高
10.10
52周最低
2.200
换手率
1.29%
市值
601.26万
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供DelMar Pharma DMPI股票价格,DelMar Pharma股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
展开 >

最近浏览

名称
价格
涨跌幅